06
Apr

Germany’s MorphoSys is moving on after the surprise cancelation of a Celgene partnership spooked investors and battered the company’s share price, with CEO Simon Moroney preaching patience for an early-stage cancer candidate.

…read more

Source: MorphoSys: That Celgene-abandoned cancer drug isn’t dead yet

    

0 No comments